Your shopping cart is currently empty

CAY10746 is a selective Rho kinase (ROCK) inhibitor, targeting ROCK I and ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be employed in the study of diabetic retinopathy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | - | In Stock | |
| 5 mg | $52 | - | In Stock | |
| 10 mg | $83 | - | In Stock | |
| 25 mg | $191 | - | In Stock | |
| 50 mg | $289 | - | In Stock | |
| 100 mg | $457 | - | In Stock | |
| 200 mg | $613 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $52 | - | In Stock |
| Description | CAY10746 is a selective Rho kinase (ROCK) inhibitor, targeting ROCK I and ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be employed in the study of diabetic retinopathy. |
| Targets&IC50 | ROCK1:14 nM, ROCK2:3 nM |
| In vitro | CAY10746 (0.1-10 µM) inhibits phosphorylation of the ROCK target protein MYPT1 in SH-SY5Y cells and also inhibits the migration of human umbilical vein endothelial cells (HUVECs).[1] CAY10746 (1 µM) protects isolated mouse retinal neurons from apoptosis and oxidative stress induced by high glucose in an in vitro model of diabetic retinopathy. It also promotes high glucose-induced vessel regression in mouse retinal explants.[1] CAY10746 is an inhibitor of Rho-associated kinase I (ROCK-I) and ROCK-II (IC50s = 14 and 3 nM, respectively).[1] |
| Molecular Weight | 457.48 |
| Formula | C26H23N3O5 |
| Cas No. | 2247240-76-0 |
| Smiles | CN(C)c1ccc(cc1)C(=O)Nc1cccc(NC(=O)COc2ccc3c(c2)occc3=O)c1 |
| Relative Density. | 1.363 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (87.44 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.37 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.